Cancer immunotherapy can have impressive long-lasting effects, but not all patients are likely to benefit from this costly treatment. ACTImmune™ helps you and your doctor to evaluate if you are likely to derive benefit from using immunotherapy.

Immunotherapy is a type of cancer treatment that uses your own immune system to fight cancer, but immunotherapy does not work for all patients. Therefore, predicting immunotherapy response before starting the treatment can help you understand if you are suitable for immunotherapy. ACTOnco™ sequences 440 cancer-related genes to predict the feasibility of using immunotherapy. ACTOnco™ is most suitable for patients who want to use immune checkpoint inhibitors

Sample types:

Typical tissue samples include FFPE (formalin-fixed and paraffin-embedded) tissue, excessive body fluids associated with cancers such as lung water or ascites, etc.

Turnaround time:

14 calendar days after samples are received